Quantcast

Latest TroVax Stories

2010-09-21 05:02:00

TUEBINGEN, Germany, September 21, 2010 /PRNewswire/ -- - New Investment Allows immatics to Perform Pivotal Study With its Lead Vaccine IMA901 in Patients With Renal Cell Carcinoma (RCC) - Study to Start in 2010 - IMA901 Phase II Trial has Shown the Potential to Confer an Overall Survival Benefit - Financing Supported by Both New and Existing Investors immatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active...

2010-09-08 13:44:51

Lung cancer researchers have identified a genetic signature that can help doctors determine which patients with early-stage non-small cell lung cancer are at high risk for developing disease recurrence and therefore may benefit from chemotherapy after surgery ("adjuvant chemotherapy"). "The findings give patients and their doctors a clearer map of the appropriate post-operative treatment route to follow. Not all patients benefit from chemotherapy after surgery and those with less aggressive...

2010-08-19 15:17:00

BRUSSELS, August 19, 2010 /PRNewswire/ -- Using the innovative technique of radioembolisation to treat patients with inoperable colorectal cancer liver metastases who have failed all standard-of-care chemotherapy options can more than double the time until their disease progresses, according to the final results of a Phase III randomised controlled trial published in the prestigious Journal of Clinical Oncology.(1) The prospective, randomised trial compared a protracted infusion of...

2010-08-03 09:55:00

COLUMBIA, Md., Aug. 3 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN) announced today that the consensus recommendations of the National Cancer Institute (NCI) Clinical Trials Planning Meeting (CTPM) for Hepatocellular Carcinoma have been released and published in the August 2010 issue of Journal of Clinical Oncology, the official publication of American Society of Clinical Oncology (ASCO). In addition to evaluating the current standard of care, the NCI panel also recommended...

2010-06-24 07:00:00

SAN CARLOS, Calif., June 24 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that the first patients have been dosed in a new Phase 1 dose-escalation clinical study to evaluate NKTR-102, the company's lead oncology compound, in combination with 5-fluorouracil (5-FU)/leucovorin in refractory solid tumor cancers. The study is being conducted at University Hospitals Case Medical Center of the Case Comprehensive Cancer Center in Cleveland, Ohio. "The dosing of the...

2010-06-07 14:28:00

BETHESDA, Md., June 7 /PRNewswire-FirstCall/ -- Northwest Biotherapeutics, Inc. ("NWBT") (OTC Bulletin Board: NWBO), developer of the DCVax® personalized cancer vaccine, today announced the release of a new detailed report by Pharmaceuticals and Biotech Analyst Dr. Navid Malik of the London-based Matrix Group. As part of an in-depth review of the history and competitive landscape of what he calls the "cancer vaccine revolution," Dr. Malik concludes that "NWBT has...

2010-06-05 19:01:00

NEW YORK, June 5 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) a development stage, specialty pharmaceutical and medical device company focused on oncology, highlighted the Phase III trial data presented on June 5 at the American Society of Clinical Oncology's 2010 Annual Meeting, comparing percutaneous hepatic perfusion (PHP) with melphalan to the best alternative care for patients with hepatic metastases from ocular or cutaneous melanoma. James F. Pingpank, MD, FACS,...

2010-06-04 13:40:06

Patients with stage III colon cancer treated with 5-FU-based chemotherapy after complete surgical removal of their tumor after 1995 had improved overall survival with no change in time to recurrence compared to patients treated before 1995. In contrast, patients with stage II colon cancer treated after 1995 had longer time to recurrence and time from recurrence to death compared to those patients treated prior to 1995, according to Mayo Clinic and Gr Hospitalier Pitie-Salpetriere, Paris,...

2010-05-28 17:51:22

Small but decisive study highlights differences in clear- and non-clear cell subtypes Of the more than 38,000 Americans diagnosed with renal cell carcinoma (RCC) each year, approximately 20 percent have non-clear cell forms of the disease. New findings shows that a non-clear cell form of kidney cancer known as papillary RCC, which accounts for 12 percent of all RCC, responds differently to sunitinib "“ a standard frontline treatment for RCC. In a small but decisive Phase II trial, the...

2010-05-13 09:11:00

COLUMBIA, Md., May 13 /PRNewswire-FirstCall/ -- Celsion Corporation (Nasdaq: CLSN) announced today that after reviewing data from 294 patients including data from 12 Japanese patients enrolled in the pivotal Phase III ThermoDox® clinical study (HEAT Study) for primary liver cancer, the Data Monitoring Committee (DMC) has recommended that Celsion continue to enroll patients in the trial. The DMC for the HEAT study is comprised of an independent group of medical and...


Word of the Day
holluschickie
  • A 'bachelor seal'; a young male seal which is prevented from mating by its herd's older males (mated bulls defending their territory).
This comes from the Russian word for 'bachelors.'
Related